Prescription drug pricing
Subtitle: cost and control concerns
By: Jonathan R. Dickson and Amy M. Woebler, editors
Series: Health care issues, costs and access; Drug transit and distribution, interception and control
Publisher: Nova Science Publishers
Published: 2011
Place of publication: New York
Language: eng
Number of pages: 139
ISBN-13: 9781613246399
Subjects: Costs and Cost Analysis; Drug Costs; Prescription pricing; Prescription Drugs; Drug Industry; Economics; Medical economics
Notes: Includes bibliographical references and index.
Table of contents: title: Prescription drugs : trends in usual and customary prices for commonly used drugs / GAO; title: Lack of therapeutically equivalent drugs and limited competition may contribute to extraordinary price increases / GAO; title: Overview of approaches to control prescription drug spending in federal programs / Statement of John E. Dicken, Director, Health Care, (GAO); title: Opening statement of U.S. Senator Amy Klobuchar, hearing on "At what cost? Egregious price increases in the pharmaceutical drug industry" / statement of Senator Charles E. Schumer, Chairman, Joint Economic Committee, Hearing on "At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry"; title: Statement of Madeline M. Carpinelli, Stephen W. Schondelmeyer, Prime Institute, College of Pharmacy, University of Minnesota, before the Joint Economic Committee, hearing on "Extraordinary price increases in the pharmaceutical market"; title: Testimony of Alan L. Goldbloom, MD, president and CEO, Children's Hospitals and Clinics of Minnesota, before the Joint Economic Committee, hearing on "At what cost? Egregious price increases in the pharmaceutical drug industry"; title: Testimony of Danielle Foltz, before the Joint Economic Committee, hearing on "At what cost? Egregious price increases in the pharmaceutical drug industry"; title: Entry threats and pricing in the generic drug industry / Brett Wendling, Steven Tenn.